TY - JOUR
AU - Ding, Huan
AB - INTRODUCTIONCancer has emerged as a major public health issue globally, lung cancer is the leading cause of cancer death in both sexes.1 By 2025, there are expected to be 2.52 million new cases of lung cancer worldwide,2 of which approximately 84% will be non‐small cell lung cancer (NSCLC).3 Most cases of NSCLC present with locally advanced or metastatic lesions at diagnosis4 with little opportunity for surgery, which result in a low overall 5‐year relative survival rate and poor prognosis.5,6In the age of precision medicine, a number of international studies have shown that targeted therapy can greatly improve the prognosis of NSCLC with corresponding driver genes.7,8 For epidermal growth factor (EGFR) mutation‐positive advanced NSCLC, several classic clinical trials have shown that EGFR tyrosine‐kinase inhibitor (EGFR‐TKI) significantly improve survival,9,10 establishing the status of EGFR‐TKI as the first‐line standard therapy. There are also many explorations on how to select targeted drugs and the deployment of targeted drugs. The longest progression‐free survival (PFS), 18.9 months, was obtained in the global multicenter Phase III FLAURA study of first‐line, third‐generation Osimertinib.11 Selecting third‐generation EGFR‐TKI after first‐line second‐generation EGFR‐TKI for Thr790Met mutation‐positive patients can achieve the longest PFS during targeted therapy, about 21–25 months.12,13 For patients with first‐line 
TI - The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis
JF - Cancer Medicine
DO - 10.1002/cam4.6453
DA - 2023-09-01
UR - https://www.deepdyve.com/lp/wiley/the-efficacy-and-safety-of-immune-checkpoint-inhibitors-for-patients-s0nBR0x5f7
SP - 18516
EP - 18530
VL - 12
IS - 18
DP - DeepDyve
ER -